Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19928346 | 0.91 | MAP3K5 (0.92) | MAP3K5AKT1 | |
| SCHEMBL16818006 | 0.91 | MAP3K5 (1.00) | MAP3K5AKT1 | |
| SCHEMBL15811987 | 0.91 | MAP3K5 (1.00) | MAP3K5AKT1 | |
| SCHEMBL15811892 | 0.91 | MAP3K5 (1.00) | MAP3K5AKT1 | |
| SCHEMBL16818030 | 0.91 | MAP3K5 (1.00) | MAP3K5AKT1 | |
| SCHEMBL15812002 | 0.91 | MAP3K5 (1.00) | MAP3K5AKT1 | |
| SCHEMBL15812046 | 0.90 | MAP3K5 (1.00) | MAP3K5AKT1 | |
| SCHEMBL19927934 | 0.90 | MAP3K5 (0.82) | MAP3K5AKT1 | |
| SCHEMBL16818077 | 0.90 | MAP3K5 (1.00) | MAP3K5AKT1 | |
| SCHEMBL16818085 | 0.90 | MAP3K5 (1.00) | MAP3K5AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3083615-B1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2019-04-17 | — | — | EP | claimed |
| US-20160318922-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2016-11-03 | — | — | US | claimed |
| EP-3083615-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | Gilead Sciences, Inc. (US) | 2016-10-26 | — | — | EP | claimed |
| US-9169243-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2015-10-27 | — | — | US | claimed |
| WO-2015095059-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2015-06-25 | — | — | WO | claimed |
| US-20150175597-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2015-06-25 | — | — | US | claimed |
| EP-3083615-B1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3083615-B1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2019-04-17 | — | — | EP | disclosed |
| US-9908875-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908875-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908875-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-20160318922-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2016-11-03 | — | — | US | disclosed |
| EP-3083615-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | Gilead Sciences, Inc. (US) | 2016-10-26 | — | — | EP | disclosed |
| US-9169243-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-9169243-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-9169243-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2015-10-27 | — | — | US | disclosed |
| WO-2015095059-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20150175597-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150175597-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150175597-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318922-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | DAPK1, BAD, FASTKD1 | MAP3K5 21/4885AKT1 442/4885 |
| US-20150175597-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | DAPK1, BAD, FASTKD1 | MAP3K5 21/4885AKT1 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.